Fri, Aug 1, 2014, 3:37 AM EDT - U.S. Markets open in 5 hrs 53 mins

Recent

% | $
Click the to save as a favorite.

Rosetta Genomics, Ltd. Message Board

neuman613 22 posts  |  Last Activity: Jul 7, 2013 12:45 PM Member since: Aug 27, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • neuman613 by neuman613 Jul 7, 2013 12:45 PM Flag

    The risk with Velti is that it stays in business. It is in a good space with outstanding operational leverage. Orbitz has the same operating model from a leverage standpoint, and just a little bit of good news can really move it. Veli's market cap is less than $100 million. Was 8 times that at one time. Past that, who the heck would short a dollar stock? The risk/reward calculation is ridiculous.

  • neuman613 neuman613 Dec 11, 2012 9:21 PM Flag

    Any possibility the news will come out at the convention they are presenting at today?

  • I've been long this puppy now and again, but even though the technology seems to be in demand and valid, the way that the company handles communications and its shareholders in general is of concern. There is a big difference between a new technology and the ability to realize profit from it. Think Tevo, Atari or Serius radio. This could be dead money forever.

  • Reply to

    Why Rosetta Genomics Is Deeply Undervalued

    by yasoocat2002 Oct 22, 2012 11:01 AM
    neuman613 neuman613 Oct 24, 2012 12:42 AM Flag

    I don't think they are ready for Accounting 101. I would start with basic math since he left out cost of goods sold.

  • Reply to

    Go Short-Go Short

    by mgdavis56 Oct 15, 2012 6:18 PM
    neuman613 neuman613 Oct 15, 2012 7:16 PM Flag

    Who shorts a $5 stock?

    Sentiment: Buy

  • Forget the Phase 1, Phase 2 #$%$. and spec buys of biotechs. Unless this thing is a total fraud, which seems unlikely since Medicare did the due diligence for us, there is almost a perfect chance that you can make money from here. What other micro-caps have a Medicare reimbursable product with a broad target market? I can't think of any. The ball is in Precision's court. If they can sell, we're good. According to Inc. Magazine, Precision sales went from $28 million in 2010 to $38 million in 2011. 200+ employees. Hold your breathe, this could be a great one.

    Sentiment: Buy

  • neuman613 neuman613 Oct 9, 2012 10:31 PM Flag

    We're not too far away. Medicare reimbursement started in July. By the next quarterly call we should see something positive. A typical nursing home bills 2 or 3 million $ per year to Medicare. I owned 5 at one time and know what I'm talking about. The market cap of Rosetta is less than $50 million. They can have $10 or $20 million in sales very quickly if the Precision sales people can get the ball rolling.

    Sentiment: Buy

  • neuman613 neuman613 Oct 7, 2012 5:47 PM Flag

    I think this news is 2 years old.

    Sentiment: Buy

  • From the RNAi blog:

    The importance of Medicare coverage (other major insurance companies usually follow Medicare’s lead) is also illustrated by the OncotypeDx test which can probably be considered the most successful of that type of expression-based molecular diagnostics in the space: launched in early 2004, it sold a mere $400,000 a quarter the year thereafter. When it, however, received Medicare coverage in early 2006, sales exploded 10-fold. Today, Genomic Health is selling around $200M worth of that test annually and sports a market capitalization of a billion US dollars- 100x that of Rosetta Genomics. Numbers for Pathway Dx are more difficult to come by as it is privately held (it completed a $30M financing in 2010 though).

    Sentiment: Strong Buy

  • Reply to

    What is ROSG worth?

    by n711rd Sep 14, 2012 10:50 AM
    neuman613 neuman613 Sep 16, 2012 2:43 PM Flag

    The market cap is about $50 million if my math is right. Title 18 reimbursement will really be the driver of course. Based on my work, other firms that look similar have market caps in the $150 million range, so I'm guessing if their technology catches on that the stock can triple from here to about $15 and then rise from there depending on sales and competition. The problem with biotech is that all the stories are so compelling. Consequently a firm that has already been approved for Medicare reimbursement has a large lead on the others. Becoming Medicare eligible is not easy and frankly shows a level of sophistication on behalf of management. Like everyone else who is long, I am hoping for the best.

    Sentiment: Buy

  • neuman613 by neuman613 Jul 25, 2005 11:46 PM Flag

    The stock will drop below 5 next week with the summer update. The September 5 call will go to 10 bid /15 ask. If this plays out, i'll be buying the 5's at 15 cents or less. The stock will then begin to rally up to $5.50+ by expiration.

  • Reply to

    Severance agreements ?? Someone explain

    by wadetaylorwontstop Jul 24, 2005 2:46 AM
    neuman613 neuman613 Jul 25, 2005 8:24 AM Flag

    U mite wont too tacke a spelling corse.

  • neuman613 by neuman613 Jun 29, 2005 2:30 PM Flag

    I was at Great America yesterday and was asking the ride operators how the summer was going. Apparently, the hot, dry weather in June has boosted attendence. They almost all told me they never saw it so busy. They told me that July is when the park really starts to fill but that this year it started in early June. I don't know if it can be extrapolated to the other parks, but one of the complaints of the last couple years was bad weather translating to lower attendence. I can't imagine a better than expected summer would not boost the price back to $6 or more.

  • Reply to

    Front end loaded

    by dcc7 Feb 28, 2005 7:17 AM
    neuman613 neuman613 Feb 28, 2005 7:33 AM Flag

    I agree. Initially I thought it was a short sqeeze, but it is still hovering here a couple weeks later. Still, my guess is that it will be trading in the mid-40's in a few months. The news is out there. Who is buying this stuff?

  • neuman613 by neuman613 Nov 8, 2003 9:57 PM Flag

    Nemomania is at its peak and "The Incredibles" does not look like a $400 million picture. Risk / reward out of sync here.

  • neuman613 by neuman613 Oct 25, 2003 8:56 PM Flag

    Steve Jobs owns over half the outstanding shares. There is also a good institutional presence. The balance is owned by the small investor. If you watch the price action, you'll notice that the average trade is a 100 share lot. The daily trading are these periphery shares. Jobs is not selling and the institutions will only sell en mass with bad news.

    That's why I think the next move will be down. Good news won't move the stock too much, since that is expected. Bad news will cause the little guy and the institutions to run. Great company, great minds, but the risk/reward in the short term is high.

  • Reply to

    #1 this week up from #5 pre order @

    by pieceofkelp Sep 23, 2003 7:55 PM
    neuman613 neuman613 Sep 23, 2003 9:48 PM Flag

    Everything is in the price. S&P wrote about 40 million home DVD sales 2 months ago. Great company, great product, great future, but priced for perfection. Run while you still can.

  • Reply to

    Shorted at $74

    by menghiinox Sep 5, 2003 12:45 PM
    neuman613 neuman613 Sep 9, 2003 12:24 AM Flag

    This is like 3 years ago when Warren Buffett was the idiot for not buying into the tech story. At the end of the day the stock price has to represent the discounted future cash flows. If you calculate that for PIXR, even without Disney's take, the numbers are still unsustainable.
    If you watch the volume, you'll see that it is trading basically in 100 share lots. The big boys are not trading this. It's the little guys. Could even be a little short squeezing right here.

  • neuman613 by neuman613 Sep 7, 2003 11:19 AM Flag

    S&P pay service rates this an aviod and Morgan Stanley, for what its worth, has a 12 month price target of $45. I think that if a deal is reached with Disney the stock will fall and if there is no deal with Disney the stock will fall. High flyers only fly for awhile i.e. FRX, KSS etc.

    Pixar is a great company with great products in an easily leveraged business. Still, it is already in the stock price. Went short at $70.

  • Reply to

    11:32AM Pixar Animation target raised

    by option_specialist Aug 29, 2003 12:17 PM
    neuman613 neuman613 Aug 29, 2003 8:19 PM Flag

    No one expects PIXAR to have another Toy Story size hit. It has to be a Monster's or a Nemo or nothing. That's a problem.

ROSG
3.9199-0.0401(-1.01%)Jul 31 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.